Target intelligence / Profile preview

Class II myosin (Myosin II)

Target
Myosin II
Molecular classification
Enzyme, Motor protein, Cytoskeletal protein
01

Overview

Class II myosin is a conventional myosin protein and the best-characterized member of the myosin superfamily[3][5]. It is composed of two heavy chains (with head, neck, and tail domains) and typically four light chains. The head domain binds both actin filaments and ATP, catalyzing its hydrolysis and converting chemical energy into directional mechanical force[1][2][7]. In muscles, myosin II forms thick filaments, enabling contraction by sliding past actin thin filaments in structures called sarcomeres[1][7]. Nonmuscle myosin II isoforms (NM2) are essential for cellular events including cytokinesis (cell division), migration, and cellular tension maintenance[2][3]. Regulation involves phosphorylation of the regulatory light chain and assembly of myosin filaments[2]. Mutations or dysregulation of class II myosins are implicated in diseases such as cardiomyopathies, cancers (by impacting cell division and migration), and certain muscle disorders[2][3][6]. Blebbistatin and related compounds can inhibit myosin II as research tools and potential drug leads, but therapeutic targeting risks include contractile dysfunction and off-target effects[2].

Other names
Conventional myosinmuscle myosinnonmuscle myosin IINM2Myh2Myh3MYH7 (paralog-specific)myosin heavy chain II
02

Mechanism of action

Inhibition of ATPase activity - Impairment of actin–myosin interaction - Disruption of filament assembly

03

Biological functions

Muscle contractionCytokinesisCell migrationCell adhesionCell polarityCellular force generation
04

Disease associations

Cardiovascular disease (e.g., cardiomyopathy)Cancer (e.g., altered cell migration and division)Muscle disorders (e.g., myopathies)Other (e.g., developmental defects)
05

Safety considerations

Cardiac toxicity (targeting contractile myosins)Muscle weakness (if perturbed in skeletal muscle)Off-target effects in nonmuscle tissueDevelopmental defects
06

Interacting drugs

Blebbistatin (selective inhibitor of nonmuscle myosin II)

3 more in the full profile.

07

Biomarkers

MYH2, MYH3, MYH7 gene expression/mutation status (specific isoforms)Phosphorylation status of regulatory light chain on S19Myosin heavy chain protein levels in cardiac/muscle biopsies

Beyond the preview

Go deeper on Class II myosin (Myosin II).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Class II myosin (Myosin II).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call